Curebase, a technology-driven clinical trial startup in San Francisco, California, has raised $40 million in Series B funding.
The circular was led by Industry Ventures, with participation from Acrew Capital, World Innovation Lab and Positive Sum, Gaingels, GGV Capital, Bold Capital and Xfund. The cycle also included a strategic investment by global biopharmaceutical company Gilead Sciences.
The company, which has raised a total of $59 million, intends to use the budget to expand its solutions.
Founded in 2017 through CEO Tom Lemberg, Curebase offers decentralized clinical trials (DCT) and patient-centered clinical trial software. The company’s hybrid and virtual study sites offer patients the opportunity to participate in clinical trials, regardless of location, through the network. provider services and home care. The platform allows sponsors and clinic physicians of all sizes to conduct clinical trials, adding personal practices, independent clinics, and giant educational study sites.
The company has conducted more than 50 studies to date, with a year-on-year growth of 300-400%.
FinPME
05/05/2022